8-K: Catheter Precision Converts $9.5M Royalty Debt to Equity

Catheter Precision, Inc. has converted approximately $9.5 million in accrued royalty rights and future royalty obligations into newly designated Series J Convertible Preferred Stock, strengthening its balance sheet.

Summary

• Catheter Precision, Inc. (VTAK) entered into Series J Exchange Agreements on February 12, 2026, to convert approximately $9.49 million in accrued royalty rights and future royalty obligations into Series J Convertible Preferred Stock.
• The conversion involves 9,489.488 shares of Series J Preferred Stock, issued to David A. Jenkins (Executive Chairman and CEO) and FatBoy Capital, LP (an entity controlled and owned by Mr. Jenkins).
• Each share of Series J Preferred Stock has a stated value of $1,000 and is convertible into common stock at a fixed price of $1.56 per share.
• The conversion of Series J Preferred Stock into common stock is contingent upon obtaining shareholder approval in accordance with the rules and regulations of the NYSE American.
• The company also announced the termination of its at-the-market (ATM) equity offering program, stating that no future equity lines of credit or forward-priced agreements are anticipated.
• The transaction aims to strengthen the company's financial position by converting short and long-term liabilities into equity and extending maturities of short-term notes.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The balance sheet restructuring and elimination of royalty obligations are beneficial, and the termination of the ATM program is a strong positive. However, the potential for future dilution from the preferred stock conversion and the related-party nature of the transaction warrant careful monitoring.

Positives

• Strengthens the balance sheet by converting approximately $9.49 million in accrued royalty liabilities into equity, reducing the company's debt burden.
• Eliminates future royalty obligations, which reduces ongoing cash outflows related to these rights.
• Termination of the at-the-market (ATM) equity offering program, with no future equity lines of credit or forward-priced agreements anticipated, signals a more stable approach to capital raising.
• The company's short-term notes have been converted to long-term by extending maturities out to two and three years, improving liquidity and financial flexibility.
• Management states the transaction reinforces institutional investor confidence and aligns long-term institutional partners.

Negatives

• The issuance of Series J Preferred Stock, convertible into 6,083,005 shares of common stock, represents potential future dilution for existing common shareholders, contingent on obtaining shareholder approval.
• The transaction involves related parties (CEO David A. Jenkins and his controlled entity FatBoy Capital, LP), which can raise corporate governance considerations regarding potential conflicts of interest.

Risks

• The issuance of common stock upon conversion of Series J Preferred Stock is subject to obtaining shareholder approval, and failure to secure this approval could impact the full realization of the conversion.
• A beneficial ownership limitation of 4.99% (adjustable up to 9.99% by the holder with 61-day notice) restricts the immediate conversion of all preferred shares into common stock by a single holder, potentially delaying full conversion.
• Future stock dividends, stock splits, or reclassifications could adjust the conversion price and the number of shares issuable upon conversion.

Future Outlook

The company aims to advance key growth initiatives, scale multiple business opportunities, and expand market presence and execution capabilities, supported by the strengthened financial position and strategic institutional capital. They anticipate no future equity lines of credit or forward-priced agreements after terminating the ATM program.

Management Comments

• "This financing and balance sheet restructuring strengthens our financial position and also reinforces institutional investor confidence in our strategy."
• "By eliminating legacy financing overhang and aligning ourselves with long-term institutional partners, we've enhanced our ability to execute with speed, discipline, and focus."
• "We now move forward from a position of financial strength, supported by capital, stability, and strategic alignment to drive meaningful shareholder value through disciplined growth."

Industry Context

StockSavvy.ai notes that the medical device sector, particularly in electrophysiology solutions, often requires significant capital for R&D and market expansion. Catheter Precision's move to convert liabilities into equity and secure institutional financing suggests a strategic effort to de-risk its balance sheet and fund growth without immediate cash outflows, a common strategy for growth-stage companies in capital-intensive industries. The termination of the ATM program could signal a shift towards more structured, less dilutive financing methods, which is generally viewed favorably by the market compared to continuous at-the-market offerings.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or competitor transactions.
• Debt-to-equity conversions are a recognized strategy for companies to improve their balance sheet liquidity and reduce debt service obligations, particularly in sectors like medical devices where long development cycles and high R&D costs are prevalent.
• The fixed conversion price of $1.56, matching the closing price on December 31, 2025, suggests the conversion was done at market value at that time, which is a standard practice for such transactions.

Corporate Governance

Related Party Transactions

• David A. Jenkins, the Company's Executive Chairman and Chief Executive Officer, received 2,491.293 shares of Series J Convertible Preferred Stock in exchange for his accrued royalty amounts and royalty rights.
• FatBoy Capital, LP, an entity controlled and owned by Mr. Jenkins, received 6,998.195 shares of Series J Convertible Preferred Stock in exchange for its accrued royalty amounts and royalty rights.

Stakeholder Impact

• Shareholders: Potential future dilution if the Series J Preferred Stock is converted into common stock, contingent on shareholder approval. However, the reduction of liabilities strengthens the company's financial position, which could be beneficial long-term. Termination of the ATM program reduces immediate dilution risk.
• Creditors: The conversion of royalty liabilities into equity reduces the company's overall debt burden, potentially improving its credit profile.
• Management (David A. Jenkins): Becomes a significant holder of Series J Preferred Stock, aligning his interests with the company's long-term equity performance, but also raising related-party transaction considerations.

Next Steps

• Obtain shareholder approval for the issuance of common stock underlying the Series J Preferred Stock in accordance with NYSE American rules.
• Continue to advance key growth initiatives and expand market presence.

Key Dates

Recommendation

The conversion of significant royalty liabilities into equity and the termination of the ATM program are positive steps towards strengthening the balance sheet and reducing future dilution risk from open-market sales. However, the potential for future dilution from the Series J Preferred Stock conversion, contingent on shareholder approval, and the related-party nature of the transaction introduce elements of uncertainty. Investors should hold to monitor the shareholder approval process and the company's execution on its growth initiatives with the improved financial flexibility.

Keywords

Catheter Precision, VTAK, Series J Preferred Stock, Convertible Preferred Stock, Debt to Equity Conversion, Royalty Rights, Balance Sheet Restructuring, SEC Filing, Corporate Governance, Shareholder Approval, Medical Device Company, Electrophysiology Solutions